Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...
A Raymond James analyst cut his price target on the specialty medical device maker. It was the second such price target cut so far this month. Raymond James prognosticator Jayson Bedford was the ...
Zacks Investment Research on MSN
3 stocks likely to gain from rising HSA contribution & Medicare premium
As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...
Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback